Published online 18 July 2008
Haematologica, Vol 93, Issue 9, 1424-1426 doi:10.3324/haematol.13059
Copyright © 2008 by Ferrata Storti Foundation

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rath, J. Articles by Jurlander, J. Search for Related Content PubMed PubMed Citation Articles by Rath, J. Articles by Jurlander, J.

Lymphoproliferative Disorders

Epstein-Barr virus reactivation is a potentially severe complication in chronic lymphocytic leukemia patients with poor prognostic biological markers and fludarabine refractory disease

Julie Rath¹, Christian Geisler¹, Claus B. Christiansen², Nina Hastrup³, Hans O. Madsen⁴, Mette K. Andersen⁵, Lone B. Pedersen¹, Jesper Jurlander¹

¹ Department of Hematology, The Leukemia Laboratory, Rigshospitalet
² Department of Microbiology, Rigshospitalet
³ Department of Pathology, Rigshospitalet
⁴ Department of Clinical Immunology, Rigshospitalet
⁵ Department of Clinical Genetics, Rigshospitalet, Denmark

Correspondence: Julie Rath, Department of Hematology 4041, Rigshospitalet, Blegdamsvej 9, 2100 København Ø, Denmark. Phone: international +45.35454045. E-mail:julie.christensen.rath{at}rh.regionh.dk

Key words: CLL, prognosis, immunodeficiency, EBV-reactivation, BLPD.

Chronic lymphocytic leukemia (CLL) patients who are refractory to, or have early relapse after, fludarabine and cyclophosphamide (FC) based therapy have a poor prognosis.¹ A major clinical problem in FC-refractory disease is a profound immunodeficiency, resulting in a high incidence of severe opportunistic infections.² The immunodeficiency may be caused either by the natural history of high-risk fludarabine-refractory CLL disease in itself and/or immuno-suppressive side effects of the CLL treatment used for this group of patients. Over a two-year period, we identified 11 CLL patients with EBV-reactivation, defined as measurable EBV-DNA copies by quantitative PCR.

All 11 patients had IgG antibodies (VCA and/or EBNA) against EBV. Ten patients had negative CMV qPCR at the time of EBV-reactivation, while one (UPN 6) had concomitant CMV-reactivation. All 11 patients had biochemical signs of hypogammaglobulinemia, while 8 (UPN 1, 2, 5–6 and 8–11) patients had neutropenia. The median age at diagnosis of CLL was 58 years (range 43–75 years). The median time from CLL diagnosis to EBV-reactivation was 4.5 years (range 1–13 years). With a follow-up time of 824 days, the median overall survival from date of EBV-reactivation was 264 days, despite aggressive rituximab based chemo-immunotherapy in symptomatic cases. Eight deaths were observed, 3 as a direct result of EBV-reactivation.

All 11 patients had high-risk disease as defined by either IGVH mutational status and/or FISH analysis of recurrent cytogenetic aberrations associated with CLL (Table 1). Ten patients (UPN 1–2 and 4–11) had received fludarabine based treatment prior to EBV-reactivation, and 9 patients (UPN 1–2, 4–6 and 8–11) had fludarabine refractory disease at the time of EBV-reactivation. Whether these observations suggest that EBV-reactivation is associated with the immuno-suppressive side-effects caused by treatment of advanced CLL cannot be determined from our data set. However, we do note that EBV-reactivation occurred before exposure to alemtuzumab in 4 patients (UPN 1, 7–8 and 11), and in one patient (UPN 3) prior to any CLL treatment. This last patient turned out to be fludarabine-resistant, did not receive rituximab, but responded well to standard alemtuzumab treatment on which EBV-copies in sequential blood samples disappeared. Of the 4 patients not treated with alemtuzumab, one developed proven EBV-driven CLL-related BLPD, one hemophagocytic syndrome, one a possible BLPD and one did not have any symptoms.

View this table: [in this window] [in a new window] [Download PPT slide]

Table 1. Characteristics of chronic lymphocytic leukemia patients with Epstein-Barr virus-reactivation.

The clinical presentation of the patients was related to the level of EBV copies/mL plasma.

1. Low-grade EBV-reactivation. Seven patients (UPN 1–7) had low EBV-levels of up to 6,600 copies/mL. The patients were either asymptomatic (UPN 1 and 4) or presented with fever, fatigue, night sweats and/or enlarged lymph nodes, that is, symptoms identical to the development of active CLL. In retrospect, UPN 5–7 were considered to have possible BLPD’s, in the absence of biopsy-proven EBV-driven disease. Five of these patients died.
   
2. High-grade EBV-reactivation. Four patients had proven EBV-associated disease (UPN 8–11). These patients had very high EBV-levels from 45,000 to 3,700,000 copies/mL plasma. One patient (UPN 8) presented with EBV-associated hemophagocytic syndrome, and died from multi-organ failure. Three patients (UPN 9–11) developed biopsy-proven EBV-positive high-grade lymphomas. In 2 of these cases (UPN 10 and 11), we isolated and sequenced tumor-specific DNA, and analyzed the Ig sequences of the tumor cell. We found that the Ig-sequences had no homology to the Ig-sequences identified in the original CLL clones of each individual. The Ig-sequences obtained provide direct evidence that the EBV-driven BLPDs originated in B-cell clones that were not associated with the original CLL clones. Of these 3 patients, one was treated successfully with R-CHOP and subsequently proceeded to RIC-HCT, while the 2 others died despite rituximab monotherapy and R-CHOP respectively.
   

EBV-reactivation in CLL patients has previously been observed in small patient cohorts. The largest study describes 5 patients with solitary BLPDs, 4 with CLL.³ All patients had received fludarabine, and 3 alemtuzumab. The lesions were clonally distinct from the original low-grade B-cell neoplasm in 3 out of 4 cases assessed. Two single case studies report on patients treated with fludarabine who develop EBV-reactivation in addition to other events.^4,5 A larger prospective study describes 4 cases of EBV-reactivation during FC therapy in 24 patients with low-grade non-Hodgkin’s Lymphoma (21 patients) and CLL (3 patients).⁶ Two of these EBV-reactivations occurred in CLL patients with partial responses to FC.

The data we present suggest that EBV-reactivation in CLL may not be rare, in fact the condition could be significantly under-diagnosed. All 11 cases had signs of severe CLL associated secondary immunodeficiency. The clinical presentation of EBV reactivation was as varied as in BLPD associated with primary immunodeficiencies, and can mimic the symptoms of active CLL. Therefore, EBV-reactivation must be considered in febrile CLL patients with high-risk biological risk features and/or fludarabine-refractory disease. In the absence of clinical trials for the management of EBV reactivation in CLL, the treatment strategy should include rituximab as in the non-CLL setting, possibly in combination with chemotherapy as recommended for Richter’s syndrome.⁷ Further research is needed to determine a threshold for differentiation between a significant and non-significant increase in EBV copies, and to determine when rituximab therapy should be initiated.

 
Funding: JJ and CG receive research funding from Roche and Bayer-Schering.

TOP References

 

1. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. J Clin Oncol 2007;25:799-804.[Abstract/Free Full Text]
2. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002;94:2033-9.[CrossRef][Medline]
3. Abruzzo L, Rosales C, Medeiros L, Vega F, Luthra R, Manning J, et al. Epstein-Barr virus-positive B-cell lympho-proliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002;26:630-6.[CrossRef][Web of Science][Medline]
4. Mercadal S, Martinez A, Nomdedeu B, Rozman M, Gaya A, Salamero O, et al. Herpes simplex and Epstein-Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabine. Eur J Haematol 2006;77:442-4.[CrossRef][Web of Science][Medline]
5. Compérat E, Delmer A, Le Tourneau A, Molina T, Diebold J, Audouin J. Concomitant Epstein-Barr virus-negative large B-cell lymphoma (Richter syndrome) and Epstein-Barr virus-positive B-cell lymphoproliferation after treatment with fludarabine and cyclophosphamide in a patient with B-cell chronic lymphocytic leukemia. Arch Pathol Lab Med 2006;130:1227-30.[Web of Science][Medline]
6. Lazzarino M, Orlandi E, Baldanti F, Furione M, Pagnucco G, Astori C, et al. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophos-phamide and dexamethasone in patients with lymphopro-liferative disorders. Br J Haematol 1999;107:877-82.[CrossRef][Web of Science][Medline]
7. Tsimberidou AM, Keating MJ. Richter's transformation in chronic lymphocytic leukemia. Semin Oncol 2006;33:250-6.[CrossRef][Web of Science][Medline]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rath, J. Articles by Jurlander, J. Search for Related Content PubMed PubMed Citation Articles by Rath, J. Articles by Jurlander, J.